Exenatide
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of exenatide are discussed. SUMMARY: Exenatide, derived from a compound found in the saliva of the Gila monster, is an incretin mimetic agent that enhances glucose-dependent insulin secretion and has several other antihyperglycemic actions. The drug is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or both but who have not achieved adequate glycemic control. Peak plasma concentration following subcutaneous administration of exenatide is attained in 2.1 hours. The mean apparent volume of distribution after administration of a single subcutaneous dose is 28.3 L. The terminal half-life of the drug is 2.4 hours. Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%. The drug is predominantly eliminated by glomerular filtration followed by proteolytic degradation. Clinical trials have shown that exenatide given subcutaneously twice daily significantly reduced glycosylated hemoglobin values when maximum doses of a sulfonylurea, metformin, or both were ineffective. The most common adverse effects are nausea, vomiting, diarrhea, jitteriness, dizziness, headache, and dyspepsia. Drug-drug interactions with digoxin, lovastatin, lisinopril, and acetaminophen have been documented. The recommended starting dosage is 5 microg subcutaneously twice daily within one hour before the morning and evening meals. CONCLUSION: Exenatide offers a novel treatment option for patients with type 2 diabetes mellitus who are refractory to metformin or sulfonylurea therapy or both.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As the first GLP-1R agonist approved for T2DM, EX is a new class of compound and a synthetic product of exendin-4, which is a compound naturally derived from the Gila monster and has multiple hypoglycemic mechanisms: inhibiting of glucagon release from α cells, slowing of gastric emptying, decreasing appetite and increasing glucose-dependent insulin secretion (12, 46, 47).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [47]
Citations
Cites
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Villhauer, E. B., Brinkman, J. A., Naderi, G. B., Burkey, B. F., Dunning, B. E., Prasad, K., Mangold, B. L., Russell, M. E., & Hughes, T. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030091l · Cited by 613
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 483
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464
Relationships of Upper Gastrointestinal Motor and Sensory Function With Glycemic Control
Rayner, C. K., Samsom, M., Jones, K. L., & Horowitz, M. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.371 · Cited by 460
Research works printed but not linked: 1
- 2000, Endocrinology, 141, 1936, 10.1210/endo.141.6.7490 · doi:10.1210/endo.141.6.7490 · Paper page
Cited by
Neuroendocrine control of food intake
Valassi, E., Scacchi, M., & Cavagnini, F. (2008) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.06.004 · Cited by 645
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237
Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics
Ding, Y., Ting, J. P., Liu, J., Al-Azzam, S., Pandya, P., & Afshar, S. (2020) · Amino Acids · doi:10.1007/s00726-020-02890-9 · Cited by 200
“Half-life of Exendin-4 was extended from 2.4 h (Bray 2006; Aroda 2018; Lear et al.”
InfluentialWerner, U., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 173
Venomics as a drug discovery platform
Escoubas, P., & King, G. F. (2009) · Expert Review of Proteomics · doi:10.1586/epr.09.45 · Cited by 172
Advances in the Treatment of Type 2 Diabetes Mellitus
Israili, Z. H. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181afbf51 · Cited by 165
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases
Zoicas, F., Droste, M., Mayr, B., Buchfelder, M., & Schöfl, C. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0997 · Cited by 122
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
Gallwitz, B. (2007) · Vascular Health and Risk Management · doi:10.2147/vhrm.2007.3.2.203 · Cited by 110
Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes
Horowitz, M., Rayner, C. K., & Jones, K. L. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0009-4 · Cited by 58
Anti-inflammatory benefits of semaglutide: State of the art
Yaribeygi, H., Maleki, M., Jamialahmadi, T., & Sahebkar, A. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100340 · Cited by 72
Kirkpatrick, A., Heo, J., Abrol, R., & Goddard, W. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218051109 · Cited by 57
Discovery of KV1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges
Gubič, Š., Hendrickx, L. A., Toplak, Ž., Sterle, M., Peigneur, S., Tomašič, T., Pardo, L. A., Tytgat, J., Zega, A., & Mašič, L. P. (2021) · Medicinal Research Reviews · doi:10.1002/med.21800 · Cited by 61
Reilly, J. B., & Berns, J. S. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00703.x · Cited by 47
Medicinal Chemistry of Incretin Mimetics and DPP‐4 Inhibitors
Zettl, H., Schubert‐Zsilavecz, M., & Steinhilber, D. (2009) · ChemMedChem · doi:10.1002/cmdc.200900448 · Cited by 50
Multilayer nanoparticles for sustained delivery of exenatide to treat type 2 diabetes mellitus
Kim, J. Y., Lee, H., Oh, K. S., Kweon, S., Jeon, O., Byun, Y., Kim, K., Kwon, I. C., Kim, S. Y., & Yuk, S. H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.040 · Cited by 40
Jensen, M. E., Galli, A., Thomsen, M., Jensen, K. L., Thomsen, G. K., Klausen, M. K., Vilsbøll, T., Christensen, M. B., Holst, J. J., Owens, A., et al. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104772 · Cited by 38
Bolli, G. B., & Owens, D. R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12253 · Cited by 36
Liu, B., Dong, Q., Wang, M., Shi, L., Wu, Y., Yu, X., Shi, Y., Shan, Y., Jiang, C., Zhang, X., et al. (2010) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.58.1474 · Cited by 41
Bain, S. C. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0073-z · Cited by 29
Pai, S., Nimma, S., Beam, W. B., VanderWielen, B. A., Kalagara, H. K. P., Bettini, L. M., Yu, S., Sharpe, E. E., Harbell, M. W., & Collaborators, M. (. A. G. I. C. (2025) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007764 · Cited by 39
Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Gallwitz, B. (2010) · Drug Safety · doi:10.2165/11319130-000000000-00000 · Cited by 24
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
Li, Y., Vaughan, K. L., Tweedie, D., Jung, Y. J., Kim, H. K., Choi, H.-I., Kim, D. S., Mattison, J. A., & Greig, N. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-53356-2 · Cited by 24
Pharmacogenomics of GLP-1 receptor agonists: Focus on pharmacological profile
Jakhar, K., Vaishnavi, S., Kaur, P., Singh, P., & Munshi, A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175356 · Cited by 25
Potential of Venom-Derived Compounds for the Development of New Antimicrobial Agents
Rabea, E. Y., Mahmoud, E. D., Mohamed, N. K., Ansary, E. R., Alrouby, M. R., Shehata, R. R., Mokhtar, Y. Y., Arullampalam, P., Hegazy, A. M., Al-Sabi, A., et al. (2025) · Toxins · doi:10.3390/toxins17050238 · Cited by 23
Silica-Based Nanomaterials for Diabetes Mellitus Treatment
Marinheiro, D., Martel, F., Ferreira, B. J. M. L., & Daniel‐da‐Silva, A. L. (2022) · Bioengineering · doi:10.3390/bioengineering10010040 · Cited by 20
Xie, Y., Zhou, Q., He, Q., Wang, X., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.008 · Cited by 18
Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices
Stauder, U., Enginee, D., Elton, H., Penfornis, A., & Edelman, S. V. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813511733 · Cited by 16
Jones, R. B., Vickers, S. P., Cheetham, S. C., Headland, K. R., Mark, M., & Klein, T. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.02.004 · Cited by 16
A guided tour through α-helical peptide antibiotics and their targets
Preußke, N., Sönnichsen, F. D., & Leippe, M. (2023) · Bioscience Reports · doi:10.1042/bsr20230474 · Cited by 16
Using adult stem cells to monitor endothelial dysfunction in diabetes mellitus
Jain, R., Awal, H. B., & Sen, S. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107588 · Cited by 15
Reddiar, S. B., Abdallah, M., Styles, I. K., Müllertz, O. O., & Trevaskis, N. L. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114339 · Cited by 10
67th Annual Meeting of the American Diabetes Association
Colca, J. R. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.10.1735 · Cited by 8
Designed Trp-Cage Proteins with Antimicrobial Activity and Enhanced Stability
Preußke, N., Lipfert, M., Rothemund, S., Leippe, M., & Sönnichsen, F. D. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00567 · Cited by 7
Knakker, B., Inkeller, J., Kovács, P., Lendvai, B., & Hernádi, I. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01981-5 · Cited by 6
A novel gene therapy platform for the treatment of type 2 diabetes and obesity
Lourie, J., Goraltchouk, A., Hollander, J. M., BERGER, N. J. A., Rosen, H. G., Fujishiro, A. A., Luppino, F., Seregin, A., Rhym, L. H., & Zou, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102739 · Cited by 6
Design and synthesis of rhamnose-modified exenatide conjugate by sortase A-mediated ligation
Li, C., Dai, S., Cao, A., Zhou, Z., & Wu, Z. (2019) · Journal of Carbohydrate Chemistry · doi:10.1080/07328303.2019.1609021 · Cited by 4
GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences
Forouzanmehr, B., Hemmati, M. A., Atkin, S. L., Jamialahmadi, T., Yaribeygi, H., & Sahebkar, A. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03384-1 · Cited by 3
Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes
Abbasi, M., Sun, K., Huggins, K. W., Heath, B., DeLoit, H., McGinness, L., & Mccamy, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.035 · Cited by 10
Coulter‐Parkhill, A., Tanday, N., Cobice, D., McLaughlin, C. M., McClean, S., Gault, V. A., & Irwin, N. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15319 · Cited by 3
66th Annual Meeting of the American Diabetes Association: 9 – 13 June 2006, Washington DC, USA
Colca, J. R. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.9.1119 · Cited by 2
Tekeli, M. Ç., Yalçın, Y., Verdi, H., Aktaş, Y., & Çelebi, N. (2024) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2024.2423823 · Cited by 1
Cristelo, C., Nunes, R., Pinto, S., Marques, J. M., Gama, M., & Sarmento, B. F. C. C. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00218 · Cited by 10
Gila Monster and Beaded Lizard
Donald G. Barceloux MD, F. (2008) · doi:10.1002/9780470330319.ch175
GLP-1 Receptor Agonists - An Anaesthesiologist’s Perspective – A Comprehensive Review
Assistant Professor, M., & Srinivasareddy, S. (2024) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v4-i08-23
McGuane, C., Farhadhar, N., Sharieff, K. A., Petrosky, S. N., & Alabasi, K. (2026) · Cureus · doi:10.7759/cureus.109731
Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review
Desai, A., Habib, H., Wahbeh, L., & Farraye, F. A. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.101023
Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists
Rosen, C. B., & Gee, D. W. (2026) · Advances in Surgery · doi:10.1016/j.yasu.2026.03.011
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
Wang, J., Romaniuk, R., & Svilenov, H. L. (2026) · FEBS Letters · doi:10.1002/1873-3468.70430
Metadata
- Authors
- Bray, G. M.
- Affiliations
- Denver Health Medical Center (US)
- Corresponding author
- Bray, Grant M.
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-03-01
- Volume
- 63
- Issue
- 5
- Pages
- 411-418
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W4233375494
- Cited by
- 52
- References
- 26
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 6 · 2023: 5 · 2022: 4 · 2021: 2 · 2020: 3 · 2019: 2 · 2016: 1 · 2014: 3 · 2013: 4 · 2012: 1
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, incretin mimetics, type 2 diabetes, glycemic control, glucose-dependent insulin secretion, pharmacokinetics, adverse drug reactions, drug-drug interactions, metformin, sulfonylureas, HbA1c
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Interactions, Humans, Hypoglycemic Agents, Peptides, Venoms, Receptors, Glucagon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.